Condition (MeSH)
Duodenal Ulcer
ClinicalTrials.gov lists 72 trials for Duodenal Ulcer or a narrower condition beneath it. Takeda has the most among industry and government lead sponsors, with 18.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
72 of the 72 trials are tagged with Duodenal Ulcer itself; the rest are tagged with a narrower condition beneath it.
When did Duodenal Ulcer trials start? (26)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 8
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2024 | 2 |
| 2023 | 5 |
| 2022 | 2 |
| 2021 | 2 |
| 2020 | 1 |
| 2019 | 1 |
| 2018 | 1 |
| 2017 | 2 |
| 2016 | 4 |
Showing 10 of 26 earlier years.
No forecast is made for this condition: it averages 2.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Duodenal Ulcer trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 2 |
| Phase 2/3 | 4 |
| Phase 3 | 23 |
| Phase 4 | 7 |
| Not applicable | 9 |
| Observational | 22 |
How many Duodenal Ulcer trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 2 |
| Active, not recruiting | 1 |
| Completed | 56 |
| Terminated | 4 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Duodenal Ulcer trials? (9)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Takeda | 18 |
| AstraZeneca | 15 |
| Boryung Pharmaceutical Co., Ltd | 3 |
| Eisai Co., Ltd. | 3 |
| Livzon Pharmaceutical Group Inc. | 3 |
Showing 5 of 9 sponsors.
Which drugs are being tested for Duodenal Ulcer? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| E3810 | 5 |
| Gefarnate | 2 |
| Omeprazole 20 mg | 2 |
| Amoxicillin | 2 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Vonoparazan | 12 |
| lansoprazole OD | 12 |
| Nexium Pill | 6 |
| 10 mg ilaprazole | 3 |
| 5 mg ilaprazole | 2 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Duodenal Ulcer trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Angina pectoris | 25 | 5 |
| Pneumonia | 23 | 10 |
| Gastric cancer | 20 | 7 |
| Cerebral infarction | 16 | 7 |
| Cardiac failure | 12 | 3 |
Showing 5 of 10 adverse events.
Which publications cover Duodenal Ulcer? (165)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Bifidobacterium breve Bif195 ameliorates aspirin-induced gastric mucosal damage: A randomised, double blind, placebo-controlled crossover trial. | Alimentary pharmacology & therapeutics | 2024 | Yes |
| Efficacy and safety of tegoprazan for duodenal ulcers in Chinese patients: a multicenter, randomized, double-blind, non-inferiority, phase III study. | Current medical research and opinion | 2024 | Yes |
| Effect and safety of anaprazole in the treatment of duodenal ulcers: a randomized, rabeprazole-controlled, phase III non-inferiority study. | Chinese medical journal | 2022 | Yes |
| Comparison of monopolar hemostatic forceps with soft coagulation versus hemoclip for peptic ulcer bleeding: a randomized trial (with video). | Gastrointestinal endoscopy | 2019 | Yes |
| Laparoscopic Repair for Perforated Peptic Ulcer Disease Has Better Outcomes Than Open Repair. | Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract | 2019 | Yes |
Showing 5 of 165 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.